Share
GLP-1 receptor agonists (GLP-1s) and SGLT-2 inhibitors lower the risk of major cardiovascular events like heart attacks and severe liver complications compared to other diabetes treatments, according to data presented at ENDO 2024. Researchers reviewed Medicare data documented from 2013 to 2020 and a large U.S. health insurance database from 2013 to 2022. They performed...
Share
Neurocrine Biosciences, Inc. on July 1 announced the U.S. Food and Drug Administration (FDA) has accepted its two New Drug Applications (NDA) with Priority Review designations for crinecerfont in the treatment of children, adolescents, and adults with classic congenital adrenal hyperplasia (CAH). If approved, crinecerfont would be the first new treatment option for CAH in...
Share
Five abstracts from Crinetics Pharmaceuticals’s clinical development programs, including four late-breaking abstracts, will be presented at the Endocrine Society’s annual meeting, ENDO 2024, taking place June 1-4, 2024 in Boston – including initial data from a Phase 2 Trial of atumelnant in congenital adrenal hyperplasia (CAH). “This year’s Endocrine Society meeting represents a major milestone for...
Share
Neurocrine Biosciences, Inc. and Diurnal Ltd., a Neurocrine Biosciences company, in May presented baseline data from the CAHtalyst™ Phase 3 studies of crinecerfont in adult and pediatric patients with congenital adrenal hyperplasia (CAH), and modified-release hydrocortisone (Chronocort®) data for a Phase 2 clinical study (CHAMPAIN) in participants with primary adrenal insufficiency and in a Phase 3 extension study in...
Share
In a first for the treatment of osteopenia, the Osteoboost — a wearable device that delivers precise vibrations to the spine and hips — promises to offer a new form of therapy for clinicians treating postmenopausal women dealing with a loss of bone density. At the beginning of 2024, the U.S. Food and Drug...
Share
The first global phase 2 study of vosoritide showed an average increased growth rate of 1.8 cm per year in children with hypochondroplasia, a genetic cause of short stature in children, according to a paper recently published in eClinicalMedicine. The clinical trial is funded by BioMarin. Researchers led by Andrew Dauber, MD, chief of Endocrinology at Children’s...
Share
Like it or not, artificial intelligence (AI) is here to stay, and its impact on both the science and practice of endocrinology will soon be quite evident. The ENDO 2024 Plenary session, “Artificial Intelligence in Health and Biomedical Research: The Future Is Now,” will no doubt answer many questions on the minds of endocrinologists in...
Share
Teprotumumab significantly improved proptosis versus placebo in longstanding/low inflammation thyroid eye disease (TED) according to data from the first placebo-controlled trial of the drug that was recently published in The Journal of Clinical Endocrinology & Metabolism. (Horizon Therapeutics funded the trial and is marketing the drug as TEPEZZA.) Researchers led by Raymond S. Douglas, MD,...
The endocrine system is a miracle of evolution — a highly complex machine that carries out multiple functions within the body with precision and efficiency. It’s no wonder that as our understanding of the endocrine system advances, the technology we use to study and care for it also becomes more advanced as it approaches the endocrine system in terms of sophistication. Whether that endocrinology technology takes the form of new, advanced medicines, sophisticated imaging and diagnostic technology, or innovative therapies that make life easier for patients, endocrine science continues to push the boundaries and enter new territory. For endocrinologists, staying informed about all of the latest advances in technology and effective treatment options mean better overall care for their patients.
This section compiles the latest news regarding technological advances in endocrinology, featuring articles written for and by the leading voices in endocrine science today. Here, you’ll find articles relating to all the most recent happenings in technology, techniques and general information of interest to endocrinologists. Keeping up with the latest advancements in the field will help you know where medicine has been, where it will advance next, and how it will look in the future. Endocrine News brings you everything you need to know about the future of endocrinology so you’ll know exactly when science catches up to your patients’ needs. The field of endocrinology continues to advance, and Endocrine News is your source for advancing your own knowledge of everything that’s going on for today and tomorrow.
